Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed duration MDT in paucibacillary leprosy (classical and modified)

N J Nadkarni, A Grugni, M S Kini

    International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association
    |March 1, 1993
    PubMed
    Summary

    Six doses of World Health Organization-Multidrug Therapy (WHO-MDT) may be sufficient for paucibacillary leprosy patients with few lesions or inactive disease. However, those with multiple lesions or active disease require careful monitoring for unfavorable events.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of commercial histamine release test and autologous serum skin test in the diagnosis of autoimmune urticaria.

    Indian journal of dermatology, venereology and leprology·2010
    Same author

    Relapses in paucibacillary leprosy after MDT--a clinical study.

    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association·1990
    Same author

    Alagille syndrome. A case report.

    Acta dermato-venereologica·1990
    Same author

    Multidrug therapy in paucibacillary leprosy--a five year experience.

    Indian journal of leprosy·1988
    Same author

    Childhood leprosy in Bombay: a clinico-epidemiological study.

    Indian journal of leprosy·1988
    Same author

    [Rehabilitative treatment of patients with primary and secondary spinal cord neoplasms].

    Minerva medica·1984

    Area of Science:

    • Dermatology
    • Infectious Diseases
    • Public Health

    Background:

    • Paucibacillary leprosy treatment typically involves a fixed duration of World Health Organization-Multidrug Therapy (WHO-MDT).
    • The optimal duration and post-therapy management strategies require ongoing evaluation to minimize unfavorable events.

    Purpose of the Study:

    • To compare the incidence of unfavorable events between classical WHO-MDT and a modified regimen with post-therapy dapsone in paucibacillary leprosy patients.
    • To identify patient subgroups at higher risk for adverse outcomes following leprosy treatment.

    Main Methods:

    • Retrospective analysis of 1022 paucibacillary leprosy patients.
    • Comparison of outcomes between patients receiving 6-dose WHO-MDT alone versus those with at least 6 months of post-MDT dapsone.

    Related Experiment Videos

  • Surveillance duration ranged from 6 months to 7 years.

    • Main Results:

    • Higher incidence of unfavorable events observed with classical MDT in patients active at treatment completion, particularly those with >2 lesions.
    • A non-significant trend of increased unfavorable events in the modified regimen for inactive patients.
    • Adverse events were more common in patients with multiple lesions and primarily occurred within the first 2 years of follow-up.

    Conclusions:

    • Six-dose WHO-MDT appears adequate for most paucibacillary leprosy patients with limited lesions or inactive disease post-treatment.
    • Caution and closer monitoring are advised for patients with multiple lesions or those remaining active after 6-dose MDT.
    • Treatment regularity and lepromin status did not correlate with unfavorable events.